Evidence map›Paper›PMID 26581194›Full record

ArticleJournal of experimental & clinical cancer research : CR2015

Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.

Gaixia He, Henghui Zhang, Jinxue Zhou, Beibei Wang, Yanhui Chen, Yaxian Kong, Xingwang Xie, Xueyan Wang, Ran Fei, Lai Wei and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
175citing papers in PubMed, 4 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

175 citing papers in PubMed, 4 syntheses or guidelines pooled it, 263 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. PD-L1Technology in cancer research & treatment
    Trial
  6. Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

115 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Gaixia HePeking University People's Hospital, Peking University Hepatology Institute, No.11 Xizhimen South Street, Beijing, 100044, China.
Henghui ZhangPeking University People's Hospital, Peking University Hepatology Institute, No.11 Xizhimen South Street, Beijing, 100044, China.
Jinxue ZhouDepartment of Hepatobiliary and Pancreatic Surgery, Henan Tumour Hospital, Zhengzhou, Henan, 450008, China.
Beibei WangInstitute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Yanhui ChenPeking University People's Hospital, Peking University Hepatology Institute, No.11 Xizhimen South Street, Beijing, 100044, China.
Yaxian KongInstitute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Xingwang XiePeking University People's Hospital, Peking University Hepatology Institute, No.11 Xizhimen South Street, Beijing, 100044, China.
Xueyan WangPeking University People's Hospital, Peking University Hepatology Institute, No.11 Xizhimen South Street, Beijing, 100044, China.
Ran FeiPeking University People's Hospital, Peking University Hepatology Institute, No.11 Xizhimen South Street, Beijing, 100044, China.
Lai WeiPeking University People's Hospital, Peking University Hepatology Institute, No.11 Xizhimen South Street, Beijing, 100044, China.
Hongsong ChenPeking University People's Hospital, Peking University Hepatology Institute, No.11 Xizhimen South Street, Beijing, 100044, China. chenhongsong@pkuph.edu.cn.
Hui ZengInstitute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zenghui@ccmu.edu.cn.
Peking University · CNPeking University People's Hospital · CNBeijing Ditan Hospital · CNCapital Medical University · CNHenan Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPD-L1 expression on neutrophils contributes to the impaired immune response in infectious disease, but the detailed role of PD-L1 expression on neutrophils in HCC remains unclear.

methodsWe investigated the phenotype and morphology of neutrophils infiltrated in tumour tissues from both patients with HCC and hepatoma-bearing mice.

resultsWe found that neutrophils dominantly infiltrated in the peritumoural region. The neutrophil-to-T cell ratio (NLR) was higher in peritumoural tissue than that in the intratumoural tissue and was negatively correlated with the overall survival of patients with HCC. Infiltrating neutrophils displayed a phenotype of higher frequency of programmed cell death ligand 1 (PD-L1) positive neutrophils. The ratio of PD-L1(+) neutrophils-to-PD-1(+) T cells was higher in peritumoural tissue and better predicted the disease-free survival of patients with HCC. We further confirmed a higher frequency of PD-L1(+) neutrophils and PD-1(+) T cells in hepatoma-bearing mice. Functionally, the PD-L1(+) neutrophils from patients with HCC effectively suppressed the proliferation and activation of T cells, which could be partially reversed by the blockade of PD-L1.

conclusionsOur results indicate that the tumour microenvironment induces impaired antitumour immunity via the modulation of PD-L1 expression on tumour infiltrating neutrophils.

Indexed as

Adaptive ImmunitySignal TransductionAnimalsB7-H1 AntigenBiomarkersCarcinoma, HepatocellularCell CountDisease Models, AnimalFemaleGene ExpressionGene Expression Regulation, NeoplasticHumansLiver NeoplasmsLymphocytes, Tumor-InfiltratingMiceNeoplasm StagingB7-H1 AntigenBiomarkersProgrammed Cell Death 1 Receptor

Identifiers

PMID26581194
PMCPMC4652417
OpenAlexW2175766278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.